Epidermal growth factor receptor (EGFR) status in chordoma

Polish Journal of Pathology

Volumn 60, Issue 2, 2009, Pages 81-87

  Ptaszyński, Konrad ^a   Szumera Ciećkiewicz, Anna ^a   Owczarek, Joanna ^a   Mrozkowiak, Anna ^a   Pekul, Monika ^a   Barańska, Joanna ^a   Rutkowski, Piotr ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Chordoma; Epidermal growth factor; Fluorescence in situ hybrydization; Immunohistochemistry

Indexed keywords

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER;

ADULT; AGED; ANEUPLOIDY; ARTICLE; BACK; CHORDOMA; COCCYGEAL BONE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SACRUM; SKULL BASE TUMOR; SPINAL CORD TUMOR;

ADULT; AGED; ANEUPLOIDY; CHORDOMA; COCCYX; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SACROCOCCYGEAL REGION; SACRUM; SKULL BASE NEOPLASMS; SPINAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79958159819     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Mirra J, Nelson S, Della Rocca C, et al. Chordoma. In: Pathology and Genetics of Tumours of Soft Tissue and Bone. Fletcher CD, Unni K, Mertens F (eds). IARC Press, Lyon 2002; 316-317.
2. Dorfmann HD, Czerniak B. Chordoma and related lesions. In: Bone and Tumors. Mosby, St. Louis 1998; 974-1007.
3. Baratti D, Gronchi A, Pennacchioli E, et al. Chordoma: natural history and results in 28 patients treated at a single institution. Ann Surg Oncol 2003; 10: 291-296.
4. Bergh P, Kindblom LG, Gunterberg B, et al. Prognostic factors in chordoma of the sacrum and mobile spine: A study of 39 patients. Cancer 2000; 88: 2122-2134.
5. Bonomi PD, Buckingham L, Coon J. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res 2007; 13 (15 Pt 2): s4606-s4612.
6. Boriani S, Bandiera S, Biagini R et al: Chordoma of the mobile spine: Fifty years of experience. Spine 2006; 31: 493-503.
7. Bjornsson J, Wold LE, Ebersold MJ, et al. Chordoma of the mobile spine. A clinicopathologic analysis of 40 patients. Cancer 1993; 71: 735-740.
8. Fujita T, Kawahara N, Matsumoto T, et al. Chordoma in the cervical spine managed with en bloc excision. Spine 1999; 24: 1848-1851.
9. Noel G, Habrand JL, Jauffret E, et al. Radiation therapy for chordoma and chondrosarcoma of the skull base and the cervical spine. Prognostic factors and patterns of failure. Strahlenther Onkol 2003; 179: 241-248.
10. Catton C, O'Sullivan B, Bell R, et al. Chordoma: Long-term follow-up after radical photon irradiation. Radiother Oncol 1996; 41: 67-72.
11. Debus J, Hug EB, Liebsch NJ, et al. Brainstem tolerance to conformal radiotherapy of skull base tumors. Int J Radiat Oncol Biol Phys 1997; 39: 967-975.
12. Igaki H, Tokuuye K, Okumura T, et al. Clinical results of proton beam therapy for skull base chordoma. Int J Radiat Oncol Biol Phys 2004; 60: 1120-1126.
13. Park L, Delaney TF, Liebsch NJ, et al. Sacral chordomas: Impact of highdose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int J Radiat Oncol Biol Phys 2006; 65: 1514-1521.
14. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20: 4292-302.
15. Fleming GF, Heimann PS, Stephens JK, et al. Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases. Cancer 1993; 72: 714-718.
16. Casali PG, Messina A, Stacchiotti S, et al. Imatinib mesylate in chordoma. Cancer 2004; 101: 2086-2097.
17. Casali PG, Stacchiotti S, Sangalli C, et al. Chordoma. Current Opin Oncol 2007; 19: 367-370.
18. Stacchiotti S, Ferrari S, Ferraresi V, et al. Imatinib mesylate in advanced chordoma: A multicenter phase. II study. J Clin Oncol 2007; 25 (18 suppl).
19. Tamborini E, Miselli F, Negri T, et al. Molecular and Biochemical Analyses of Platelet-Derived Growth Factor Receptor (PDGFR) B, PDGFRA, and KIT Receptors in Chordomas. Clin Cancer Res 2006; 12: 6920-6928.
20. Orzan F, Terreni MR, Longoni M, et al. Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas. Oncol Rep 2007; 18: 249-252.
21. Weinberger PM, Yu Z, Kowalski D, et al. Differential expression of epidermal growth factor receptor c-Met and HER2/neu in chordoma compared with 17 other malignancies. Arch Otolaryngol Head Neck Surg 2005; 131: 707-711.
22. Hof H, Welzel T, Debus J. Effectiveness of cetuximab/ /gefitinib in the therapy of a sacral chordoma. Onkologie 2006; 29: 572-574.
23. De Luca A, Carotenuto A, Rachiglio A, et al. The role of the EGFR signaling in tumor microenviroment. Cell Physiol 2008; 214: 559-567.
24. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366: 2-16.
25. Normanno N, Maiello MR, Mancino M, et al. Small molecule epidermal growth factor receptor tyrosine kinase inhibitors: an overview. J Chemother 2004; 16 Suppl 4: 36-40.
26. Shepard HM, Brdlik CM, Schreiber H. Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest 2008; 118: 3574-3581.
27. Zhang H, Berezov A, Wang Q, et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 2007; 117: 2051-2052.
28. Ciardiello F, Tortora G. EGFR Antagonists in Cancer Treatment. N Engl J Med 2008; 358: 1160-1174.
29. Saltz L, Rubin M, Hochster H. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory. colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20.
30. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27: 2091-2096.
31. Tamayama C, Maruyama K. Expression of EGF receptor and c-neu oncogene product in chordomas. Gan No Rinsho 1990; 36: 773-776.
32. Fasing JH, Dupont WD, LaFleur BJ, et al. Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordom. Neuropathol Appl Neurobiol 2008; 34: 95-104.
33. Normanno N, Maiello MR, De Luca A. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with complex mechanism of action? J Cell Physiol 2003; 194: 13-19.
34. Galizia G, Lieto E, De Vita F, et al. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 2007; 26: 3654-3660.
35. Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 2007; 298: 70-82.
36. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-1810.
37. Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007; 25: 3238-3245.
38. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in nonsmall-cell lung cancer. J Natl Cancer Inst 2005; 97: 643-655.
39. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279-286.
40. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-144.
41. Gridelli C, Bareschino MA, Schettino C, et al. Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist 2007; 12: 840-849.
42. Moroni M, Sartore-Bianchi A, Veronese S, et al. EGFR FISH in colorectal canser: what is the current reality? Lancet Oncol 2008; 9: 402-403.
43. van Krieken JH, Jung A, Kirchner T, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008; 453: 417-431.